Oncotarget: An exploratory study of metformin and rapamycin as maintenance therapy
Volume 11, Number 21 of @Oncotarget reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with rapamycin, stratified by prior treatment with FOLFIRINOX. Metformin +/ rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival.
Dr. Dung T. Le from The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 21287 said, ... continue reading >>
Oncotarget: Scent test to screen for early-stage pancreatic cancer
Oncotarget published "Scent test using Caenorhabditis elegans to screen for early-stage pancreatic cancer" which reported that although early detection and diagnosis are indispensable for improving the prognosis of patients with pancreatic cancer, both have yet to be achieved. Except for pancreatic cancer, other cancers have already been screened through scent tests using animals or microorganisms, including Caenorhabditis elegans.
In this study, the authors organized a nationwide study group... continue reading >>
Oncotarget: General anesthesia for pancreatic cancer surgery
Oncotarget published "Perioperative changes in the plasma metabolome of patients receiving general anesthesia for pancreatic cancer surgery" which reported that little is known about the impact of anesthesia on the plasma metabolome, although many metabolites have been shown to modulate the function of various immune cells, making it particularly interesting in the context of oncological surgery.
In this study longitudinal dynamics in the plasma metabolome during general anesthesia in patients ... continue reading >>
Oncotarget: A comprehensive analysis of clinical trials in pancreatic cancer
The cover for issue 38 of Oncotarget features Figure 3, "Summary of the time and cost for drug development (modified from DiMasi et al [2016]," by Katayama, et al. which reported that Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies.
In this study, the Oncotarget authors perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies.
In this study, ... continue reading >>
The cover for issue 10 of Oncotarget features Figure 3, "Overall survival (OS) for high (red) versus low (black) risk groups in the (A) OSU, (B) TCGA, and (C) SNU resected cohorts," by Wolfe, et al.
Digital mi RNA expression profiling was performed and risk scores were calculated based on the expression levels of the four most significantly correlated mi RNAs and dichotomized about the median to detect correlations between risk group, LRR and overall survival.
On multivariable analysis, the... continue reading >>
Dynamic changes during the treatment of pancreatic cancer
This detailed analysis of the clinical descriptions, imaging, pathology, molecular and cellular evolution of the tumors, treatments and responses to chemotherapy, targeted therapies and immunotherapies as well as attempts at the development of personalized medical treatments for a single patient should provide a valuable guide to future directions in cancer treatment.
"They all sacrificed time and effort from other research projects and activities, because they all came to appreciate the... continue reading >>
Oncotarget | Prognostic and predictive factors in pancreatic cancer
Oncotarget Volume 11, Issue 10 reported that there are not standardized predictive biomarkers able to identify patients who benefit most from treatments.
The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer.
Dr. Fabrizio Citarella from the Department of Medical Oncology, University Campus Bio-Medico, Rome 00128... continue reading >>
Oncotarget: The role of circulating miRNAs and CA19-9 in pancreatic cancer diagnosis
Oncotarget published "The role of circulating miRNAs and CA19-9 in pancreatic cancer diagnosis" which reported that the expression profile of microRNAs was measured in all groups using RT-PCR, serum CA19-9 levels were determined in PA and PC. In tissue samples, there was a difference in the expression of miRNAs-21, -210 across the PAt, PC and PPT groups.
The combination of miRNAs-21, -210 tissue expression and serum CA19-9 showed 100% accuracy in the diagnosis of PA, as well as miR-181c... continue reading >>
Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC
